Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXIL + Thalidomide + Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT00097981Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2005
- Primary completion
- Oct 2007
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin liposomal in multiple myeloma (MM) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Complete Response Rate. Started Jan 2005; status: completed.
02
Drugs
doxorubicin liposomal
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00097981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097981.